Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2019 - 2026)

Taysha Gene Therapies has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $300.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $300.4 million, up 117.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 90.41% YoY), and the FY2025 annual result was $343.3 million, up 114.09% from the prior year.
• Liabilities and Shareholders Equity came in at $300.4 million for Q1 2026 at Taysha Gene Therapies, down from $343.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $343.3 million in Q4 2025 to a low of $81.5 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $166.0 million (2022), against an average of $189.6 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 53.76% in 2022 and soared 145.75% in 2024, its largest moves.
• Taysha Gene Therapies' Liabilities and Shareholders Equity stood at $126.3 million in 2022, then surged by 36.79% to $172.7 million in 2023, then slipped by 7.16% to $160.4 million in 2024, then soared by 114.09% to $343.3 million in 2025, then fell by 12.52% to $300.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $300.4 million (Q1 2026), $343.3 million (Q4 2025), and $316.6 million (Q3 2025), per Business Quant data.